4 Hrs
Source:
الخليج
India authorizes Japanese dengue vaccine
India has for the first time approved the sale of the Japanese dengue vaccine "Kydnga," manufactured by Takeda, which is recommended in a two-dose regimen for individuals aged 4 to 60 years, in its domestic market. The vaccine is administered in approximately 40 countries and aims to combat the global threat faced by nearly half of the world's population, with over a million cases reported in India since 2021, including at least 1,500 deaths. Dengue causes a fever and other symptoms, while India is also awaiting results from trials of another single-dose vaccine currently under development.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)